Literature DB >> 2345300

Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis.

K Hansen1, M Cruz, H Link.   

Abstract

Cerebrospinal fluid (CSF) and serum from 45 patients with lymphocytic meningoradiculitis were examined by isoelectric focusing combined with immunoblotting to detect Borrelia burgdorferi-specific oligoclonal immunoglobulin G (IgG) bands. In pretreatment samples, 35 patients (78%) showed B. burgdorferi-specific oligoclonal IgG in CSF indicative of intrathecal antibody production. At 2, 3-6, and 6 weeks after onset, respectively, such bands were present in 5 (42%) of 12, 21 (88%) of 24, and in all of 9 patients (100%). Up to 1 year after therapy, specific oligoclonal bands in CSF tended to remain unchanged despite clinical recovery. B. burgdorferi-specific oligoclonal bands in serum were found in 7 patients. These bands had identical migration patterns as in CSF, but were fewer in number and in some patients showed a temporal evolution different from their CSF counterpart. Not all oligoclonal IgG in CSF reacted with B. burgdorferi. The 41-kDa flagellar antigen was shown to be a major antigen in the intrathecal immune response. The demonstration of B. burgdorferi-specific oligoclonal IgG in CSF is a sensitive and reliable indicator of Lyme neuroborreliosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345300     DOI: 10.1093/infdis/161.6.1194

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Lyme borreliosis: host responses to Borrelia burgdorferi.

Authors:  A Szczepanski; J L Benach
Journal:  Microbiol Rev       Date:  1991-03

2.  Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins.

Authors:  Andrew J Nowalk; Robert D Gilmore; James A Carroll
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Antibodies in multiple sclerosis oligoclonal bands target debris.

Authors:  Ryan C Winger; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-28       Impact factor: 11.205

4.  Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1.

Authors:  Anna Grahn; Marie Studahl; Staffan Nilsson; Elisabeth Thomsson; Malin Bäckström; Tomas Bergström
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

5.  Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction.

Authors:  A M Lebech; K Hansen
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  Intrathecal immune response in patients with neuroborreliosis: specificity of antibodies for neuronal proteins.

Authors:  R Kaiser
Journal:  J Neurol       Date:  1995-05       Impact factor: 4.849

7.  Comparison of two methods for detecting intrathecal synthesis of Borrelia burgdorferi-specific antibodies and PCR for diagnosis of Lyme neuroborreliosis.

Authors:  R Zbinden; D Goldenberger; G M Lucchini; M Altwegg
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

8.  Acute and chronic neuroborreliosis with and without CNS involvement: a clinical, MRI, and HLA study of 27 cases.

Authors:  H Krüger; E Heim; B Schuknecht; S Scholz
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

9.  Pathogen specificity and autoimmunity are distinct features of antigen-driven immune responses in neuroborreliosis.

Authors:  Sandra Kuenzle; Hans-Christian von Büdingen; Mirjam Meier; Melanie D Harrer; Eduard Urich; Burkhard Becher; Norbert Goebels
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Serologic response to the Borrelia burgdorferi flagellin demonstrates an epitope common to a neuroblastoma cell line.

Authors:  E Fikrig; R Berland; M Chen; S Williams; L H Sigal; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.